

Supplementary

Table S1 Baseline of breast cancer patients in diabetes group and control group

Variables	Diabetes Group (n=37)	Control Group (n=50)	χ^2	P value
menopausal status				
Pre-menopausal	18	24	0.004	0.952
Post menopausal	19	26		
Histologic type				
Special type	6	10	0.203	0.652
Non special type	31	40		
Axillary lymph node status				
No	23	33	0.137	0.712
Metastasis	14	17		
Clinical stage TNM stages				
I + II _a	21	22	1.384	0.239
II _b + III	16	28		
ER				
Positive	25	30	0.524	0.469
Negative	12	20		
PR				
Positive	21	29	0.013	0.908
Negative	16	21		
HER-2				
Negative	27	37	0.012	0.914
Positive	12	13		
Ki67				
≥30%	20	34	1.757	0.185
<30%	17	16		

ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.

Table S2 The primers of hsa-miR-29a and U6

U6	F primer	ATTGGAACGATACAGAGAAGAT
	R primer	GGAACGCTTCACGAATTT
hsa-miR-29a	F primer	TTTCCCTGGGTCTGGGCTGGGGC
	R primer	CCAGCCCAGACCCAGGGAAATGG

Table S3 Animal characteristic

	anti-miR-29a	vector	others
weight(g)	26.22± 0.3825	26.15 ± 0.3888 [*]	28.03 ± 0.7939 ^{**}
fasting blood glucose(mmol/l)	20.77 ± 0.5116	20.43 ± 0.6912 [*]	10.15 ± 0.8611 [#]

Values are presented as mean ± SEM. *P>0.05 significant differences compared with anti-miR-29a group. **P > 0.05 significant differences compared with anti-miR-29a group OR vector group. #P <0.001 significant differences compared to anti-miR-29a group OR vector group